Validation of a New Methodology to Create Oral Drugs beyond the Rule of 5 for Intracellular Tough Targets

Citations Over TimeTop 1% of 2023 papers

Abstract

Establishing a technological platform for creating clinical compounds inhibiting intracellular protein-protein interactions (PPIs) can open the door to many valuable drugs. Although small molecules and antibodies are mainstream modalities, they are not suitable for a target protein that lacks a deep cavity for a small molecule to bind or a protein found in intracellular space out of an antibody's reach. One possible approach to access these targets is to utilize so-called middle-size cyclic peptides (defined here as those with a molecular weight of 1000-2000 g/mol). In this study, we validated a new methodology to create oral drugs beyond the rule of 5 for intracellular tough targets by elucidating structural features and physicochemical properties for drug-like cyclic peptides and developing library technologies to afford highly N-alkylated cyclic peptide hits. We discovered a KRAS inhibitory clinical compound (LUNA18) as the first example of our platform technology.

Related Papers

• → Antibody-enabled small-molecule drug discovery(2012)79 cited
• → The Emergence of Cyclic Peptides: The Potential of Bioengineered Peptide Drugs(2014)38 cited
• → Peptide oligomers from ultra-short peptides using sortase(2017)14 cited
• → A cyclic peptide with high affinity to α-bungarotoxin protects mice from the lethal effect of the toxin(2001)6 cited
• Synthesis and biological studies of cyclic peptides(2018)